Level C· Early human research exploring benefitsCase Report / SeriesEurope PMCOpen access

Human Umbilical Cord Mesenchymal Stem Cells for Severe Neurological Sequelae due to Anti- N -Methyl-d-Aspartate Receptor Encephalitis: First Case Report

Nguyen Thanh L., Hoang VT., Le Thu H., Nguyen PAT., Hoang DM., Ngo DV.

Case Report / Series on Autoimmune Research, published in Cell Transplant (2022) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Cell Transplant (2022)
Reported sample size
—
Source database
Europe PMC
PMID
35815930
PMCID
PMC9277426
DOI
10.1177/09636897221110876
Citations
4

Abstract (original English)

Anti- N -methyl- d -aspartate (NMDA) receptor encephalitis is caused by altered patient immune reactions. This study reports the first patient with severe neurologic sequelae after NMDA receptor encephalitis treated with allogeneic umbilical cord-derived mesenchymal stem/stromal cells (UC-MSCs). A 5-year-old girl was diagnosed with NMDA receptor encephalitis and treated with immunosuppressive medicaments and intravenous immunoglobulin (IVIG). Despite intensive therapy, the patient's condition worsened so that allogenic UC-MSC therapy was contemplated. The patient received three intrathecal infusions of xeno- and serum-free cultured UC-MSCs at a dose of 10 6 cells/kg. At baseline and after each UC-MSC administration, the patient was examined by the German Coma Recovery Scale (CRS), the Gross Motor Function Classification System (GMFCS), the Gross Motor Function Measure-88 (GMFM-88), the Manual Ability Classification System (MACS), the Modified Ashworth Scale, and the Denver II test. Before cell therapy, she was in a permanent vegetative state with diffuse cerebral atrophy. Her cognition and motor functions improved progressively after three UC-MSC infusions. At the last visit, she was capable of walking, writing, and counting numbers. Control of urinary and bowel functions was completely recovered. Cerebral atrophy was reduced on brain magnetic resonance imaging (MRI). Overall,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Mesenchymal Stem CellsUmbilical CordHumansAtrophyDisease ProgressionReceptors, N-Methyl-D-AspartateChild, PreschoolFemaleAnti-N-Methyl-D-Aspartate Receptor Encephalitis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research